Blood transfusion diagnostics market seen reaching $6.86 billion by 2030

The Business Research Company says the blood transfusion diagnostics market will grow from $5.35 billion in 2026 to $6.86 billion by 2030, driven by more surgeries, more blood-related disease screening and wider use of automated testing. North America led the market in 2025 and is expected to keep that position.

Why it matters: - Blood transfusion diagnostics help ensure donor-recipient compatibility and reduce the risk of transfusion-related complications. - Market growth points to rising demand for safer, faster blood screening as hospitals, blood banks and labs handle more transfusions and disease testing. - The market’s projected rise to $6.86 billion by 2030 signals continued investment in automation, rapid testing and quality control.

What happened: - The Business Research Company released its 2026 blood transfusion diagnostics market report covering market size, trends and global forecasts for 2026-2035. - The market is expected to grow from $4.96 billion in 2025 to $5.35 billion in 2026, a 7.9% CAGR. - The report projects the market will reach $6.86 billion by 2030, growing at a 6.4% CAGR. - North America was the largest regional market in 2025, followed by Western Europe. - The report also covers Asia-Pacific, South East Asia, Eastern Europe, South America, the Middle East and Africa. - The company offers a free sample report and a full market report.

The details: - Blood transfusion diagnostics include pre-transfusion tests such as blood grouping and disease screening. - The tests are used to identify blood types and screen for infectious agents before blood is transferred between donors and recipients. - The report links historical growth to limited access to advanced blood diagnostic instruments, manual blood grouping, higher hospital transfusion volumes, more transfusion-transmissible infections, and a lack of standardized reagents and kits. - Future growth is tied to high-throughput automated blood screening systems, nucleic acid amplification testing, rapid testing methods, higher spending on blood banks and diagnostic labs, digital and AI-enabled diagnostics, and growth in plasma fractionation and research. - The report says emerging trends include faster blood typing, broader automated blood processing, expanded disease screening and stronger standardization and quality control. - One growth driver is the rise in surgical procedures worldwide, which increases demand for blood screening and matching. - The American Society of Plastic Surgeons reported a 7% increase in minimally invasive procedures in 2023, with hand surgeries reaching 207,887 cases, up 2% from the prior year. - The rising incidence of blood-related disorders is also supporting demand for transfusion diagnostics. - The American Cancer Society reported about 59,610 new leukemia cases and 23,710 leukemia-related deaths in January 2023, including about 20,380 new acute myeloid leukemia cases.

Between the lines: - The market forecast suggests the biggest commercial opportunity is shifting from manual processes to automation and digital tools. - Regional leadership in North America likely reflects stronger healthcare infrastructure and more established testing capacity. - Disease burden and procedure volume are both pushing the market, which makes transfusion diagnostics a defensive healthcare category rather than a discretionary one.

What's next: - Blood banks and diagnostic labs are likely to keep investing in automation, rapid screening and AI-enabled workflows. - The report expects North America to maintain its lead, while other regions grow at different rates depending on infrastructure and disease prevalence. - More focus on standardization and quality control should shape product development and purchasing decisions through 2030.

The bottom line: - Blood transfusion diagnostics is moving from a manual, compliance-driven function toward a technology-led growth market with steady demand through the end of the decade.